The pathophysiology of malignant glioma and treatment strategies

我们一直在研究恶性神经胶质瘤细胞生物学分析中的三个主题； 1.恶性胶质瘤细胞高表达细胞因子的鉴定及功能分析。 2. 导致神经胶质瘤细胞恶性肿瘤的基因和蛋白质的分子鉴定。 3.神经胶质瘤干细胞的表征。我们发现多种细胞因子如MCP-1和IL-6在恶性胶质瘤细胞中过度表达，它们有助于恶性胶质瘤细胞的增殖或侵袭。我们利用DNA微阵列、DNA Tip和蛋白质组学的方法分析了与胶质瘤细胞恶性相关的基因。但这些基因是否参与胶质瘤细胞恶性信号的传递还需要进一步研究。我们已经证实，从神经胶质瘤患者身上建立的神经胶质瘤干细胞具有在小鼠大脑中生长的潜力，并正在研究其对化疗或放疗等肿瘤治疗的耐药性。基于我们在这些研究中发现的新发现，我们一直在致力于构建新的分子靶向疗法，例如阻断自分泌细胞因子环，抑制神经胶质瘤细胞恶性肿瘤中的激活信号。此外，我们一直在尝试建立一种新技术，利用纳米技术通过血脑屏障输送药物。我们需要进一步研究其在神经胶质瘤患者治疗中的临床治疗方法的应用。

We have been investigating for three subjects in analysis of malignant glioma cell biology; 1. Identification and functional analysis of cytokines high expressing in malignant glioma cells. 2. Molecular identification of genes and proteins contributing to malignancy in glioma cells. 3. Characterization of glioma cancer stem cells. We have found that several cytokines such as MCP-1 and IL-6 were overexpressed in malignant glioma cells and they contributed to proliferation or invasion of malignant glioma cells. We have analyzed, the genes related to the malignancy of glioma cells using the methods of DNA microarray, DNA tip and proteomix. However it is necessary for furthermore investigation to confirm whether these genes are involved in the signal of the malignancy of glioma cells. We have confirmed that the glioma cancer stem cells established from the patients with glioma had the potential to grow up in the brain of the mouse and have been investigating for the quality of resistance for the tumor therapy such as chemotherapy or radiotherapy.Based on the new discovery we have found in these study, we have been tackling to make up the new molecular targeting therapy such as to block the autocline cytokines loop, to suppress the activating signal in the malignancy of glioma cells. Furthermore we have been trying to establish a new technology to deliver the drug through the blood-brain barrier using the nano-technology. We need furthermore investigation for the application to clinical therapeutical methods in the therapies for glioma patients.